Adderall IR Dosing and Management for ADHD
For children ≥6 years and adolescents with ADHD, start Adderall IR at 5 mg once or twice daily, titrate by 5 mg weekly intervals to optimal response (typically 18-26 mg/day for amphetamines), rarely exceeding 40 mg/day total; for children 3-5 years, start at 2.5 mg daily with 2.5 mg weekly increments. 1
Dosing Guidelines by Age
Children 3-5 Years
- Starting dose: 2.5 mg daily
- Titration: Increase by 2.5 mg at weekly intervals
- Maximum: Rarely exceed 40 mg/day total
- Timing: First dose on awakening; additional doses at 4-6 hour intervals 1
Children ≥6 Years and Adolescents
- Starting dose: 5 mg once or twice daily
- Titration: Increase by 5 mg at weekly intervals
- Optimal range: Recent network meta-analysis shows peak net clinical benefit at 12-26 mg/day for amphetamines (specifically 18-20 mg/day) 2
- Maximum: 40 mg/day (rarely necessary) 1
- Timing: First dose on awakening; 1-2 additional doses at 4-6 hour intervals 1
Adults
- Starting dose: 5 mg once or twice daily (extrapolated from pediatric dosing)
- Effective range: Studies show mean effective doses of 10.77 mg/day in responders 3, though higher doses up to 50 mg/day may be needed before plateau effect 4
- Maximum: 60 mg/day per FDA labeling 1
Critical Pre-Treatment Assessment
Before initiating Adderall IR, you must assess for:
- Cardiac disease: Perform careful personal and family history of sudden death or ventricular arrhythmia, plus physical examination 1
- Tics/Tourette's syndrome: Evaluate family history and clinically assess for motor or verbal tics 1
- Psychiatric comorbidities: Particularly anxiety disorders—amphetamines precipitated acute anxiety in 57% (4/7) of patients with comorbid anxiety 3
Contraindications and Cautions
- Absolute contraindications: Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate-to-severe hypertension, hyperthyroidism, glaucoma, agitated states, history of drug abuse, during or within 14 days of MAOI use, hypersensitivity to amphetamines
- High-risk populations: Patients with anxiety disorders (may precipitate acute anxiety symptoms) 3
- Preschool children (under 6 years): Use with restraint—less efficacious and higher adverse event rates than in school-age children; reserve for very high severity cases 5
Monitoring Parameters
Monitor at each visit:
- Height and weight (decreased appetite is common) 5
- Pulse and blood pressure (amphetamines increase both) 5
- Sleep disturbances (avoid late evening doses due to insomnia) 1
- Psychiatric symptoms: Suicidality, clinical worsening, mood lability, anxiety 5
- Headaches and gastrointestinal symptoms 5
Evidence-Based Dosing Strategy
The most recent dose-response network meta-analysis 2 demonstrates that for amphetamines in children/adolescents:
- Efficacy increases with dose up to approximately 25 mg/day, then plateaus
- Adverse event-related discontinuation rises steadily with higher doses
- Optimal balance of benefit-to-harm occurs at 12-26 mg/day (peak 18-20 mg/day)
This contrasts with the FDA maximum of 40 mg/day 1, suggesting that doses above 26 mg/day offer diminishing returns with increasing adverse effects.
Clinical Pearls
Stimulants have large effect sizes (1.0) compared to non-stimulants (0.7) 6, making them first-line pharmacotherapy for moderate-to-severe ADHD. However, approximately 40% of patients respond to both methylphenidate and amphetamine, while 40% respond to only one—response is idiosyncratic 6.
Adderall IR is a controlled substance (Schedule II) with high abuse potential 1. Real-world data shows 30.7% of adults use short-acting monotherapy, with average daily consumption of 2.1 tablets 7, suggesting many patients require multiple daily doses.
Timing matters: Give first dose upon awakening, with additional doses (1-2) at 4-6 hour intervals 1. Avoid late evening doses to prevent insomnia 1.
Treatment Context
Pharmacotherapy should be integrated with behavioral interventions and psychoeducation 5. For school-age children and adolescents, severity determines treatment approach: moderate cases can receive medication while severe cases should receive it 5. Use shared decision-making involving parents/caregivers and the patient (age-appropriately) 5.
For preschool children, behavioral interventions are first-line; pharmacotherapy is reserved only for very high severity cases due to lower efficacy and higher adverse event rates in this age group 5.